XTX Topco Ltd Acquires 32,201 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

XTX Topco Ltd increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 176.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,464 shares of the company’s stock after acquiring an additional 32,201 shares during the period. XTX Topco Ltd owned approximately 0.05% of Intellia Therapeutics worth $1,129,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its stake in shares of Intellia Therapeutics by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock worth $21,350,000 after buying an additional 18,987 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Intellia Therapeutics by 5.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,170,829 shares of the company’s stock worth $35,704,000 after purchasing an additional 60,748 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Intellia Therapeutics by 23.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,204 shares of the company’s stock worth $242,000 after purchasing an additional 1,553 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in Intellia Therapeutics during the 4th quarter valued at about $206,000. Finally, Norges Bank purchased a new stake in Intellia Therapeutics during the 4th quarter valued at about $16,348,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $21.88 on Friday. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -4.08 and a beta of 1.77. Intellia Therapeutics, Inc. has a 1 year low of $19.21 and a 1 year high of $34.87. The firm has a fifty day moving average price of $23.26 and a 200-day moving average price of $24.16.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. During the same period last year, the firm posted ($1.40) EPS. The firm’s quarterly revenue was down 48.5% on a year-over-year basis. Equities research analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NTLA. Truist Financial reiterated a “buy” rating and issued a $120.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. Stifel Nicolaus reduced their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. JPMorgan Chase & Co. decreased their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $61.77.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.